Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 19, 2022

SELL
$11.63 - $21.55 $407 - $754
-35 Reduced 0.33%
10,482 $159,000
Q1 2022

May 04, 2022

SELL
$16.63 - $27.73 $16,047 - $26,759
-965 Reduced 8.4%
10,517 $214,000
Q4 2021

Jan 31, 2022

SELL
$20.7 - $34.18 $70,131 - $115,801
-3,388 Reduced 22.78%
11,482 $335,000
Q3 2021

Oct 29, 2021

SELL
$19.05 - $28.32 $84,562 - $125,712
-4,439 Reduced 22.99%
14,870 $320,000
Q2 2021

Aug 11, 2021

SELL
$18.93 - $25.65 $200,146 - $271,197
-10,573 Reduced 35.38%
19,309 $495,000
Q1 2021

May 04, 2021

SELL
$11.86 - $21.77 $139,675 - $256,385
-11,777 Reduced 28.27%
29,882 $544,000
Q4 2020

Feb 11, 2021

SELL
$7.25 - $11.76 $166 - $270
-23 Reduced 0.06%
41,659 $480,000
Q3 2020

Nov 05, 2020

SELL
$6.53 - $8.6 $5,452 - $7,181
-835 Reduced 1.96%
41,682 $317,000
Q2 2020

Aug 12, 2020

SELL
$4.11 - $6.78 $982 - $1,620
-239 Reduced 0.56%
42,517 $279,000
Q1 2020

May 11, 2020

SELL
$3.15 - $7.39 $4,069 - $9,547
-1,292 Reduced 2.93%
42,756 $218,000
Q4 2019

Feb 05, 2020

SELL
$5.01 - $8.16 $32,339 - $52,672
-6,455 Reduced 12.78%
44,048 $337,000
Q3 2019

Oct 30, 2019

SELL
$5.07 - $7.08 $2,981 - $4,163
-588 Reduced 1.15%
50,503 $267,000
Q2 2019

Jul 19, 2019

BUY
$3.43 - $5.6 $3 - $5
1 Added 0.0%
51,091 $286,000
Q1 2019

May 13, 2019

SELL
$3.56 - $4.82 $996 - $1,349
-280 Reduced 0.55%
51,090 $217,000
Q4 2018

Feb 11, 2019

SELL
$4.04 - $6.75 $1,733 - $2,895
-429 Reduced 0.83%
51,370 $210,000
Q3 2018

Nov 06, 2018

BUY
$4.28 - $7.32 $77 - $131
18 Added 0.03%
51,799 $355,000
Q2 2018

Jul 31, 2018

SELL
$3.1 - $3.93 $5,208 - $6,602
-1,680 Reduced 3.14%
51,781 $203,000
Q1 2018

May 14, 2018

BUY
$2.32 - $4.22 $124,029 - $225,605
53,461 New
53,461 $156,000

Others Institutions Holding CDMO

About Avid Bioservices, Inc.


  • Ticker CDMO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,167,500
  • Market Cap $776M
  • Description
  • Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant pro...
More about CDMO
Track This Portfolio

Track Commonwealth Equity Services, LLC Portfolio

Follow Commonwealth Equity Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Commonwealth Equity Services, LLC with notifications on news.